Size
50µg
Catalog no#
PKSH033121-50µg
Price
376 EUR
Activity
NA
Fusion tag
C-6His
Accession
Q9HBG7
AP Mol Mass
75 kDa
Mol Mass
45.6 kDa
Tissue
lymphocyte
Expressed Host
Human cells
Sequence
Lys48-Lys454
Group
recombinants
Source
Recombinants or rec. proteins
Purity
＞95% as determined by reducing SDS-PAGE.
Reconstitution
Please refer to it for detailed information.
Endotoxin
＜1.0 EU per µg as determined by LAL test.
Formulation
Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.
Description
Antigens are peptides or recombinant or native dependent on the production method.
Shipping
The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Synonym
T-lymphocyte surface antigen Ly-9; Cell surface molecule Ly-9; Lymphocyte antigen 9; SLAM family member 3; SLAMF3; Signaling lymphocytic activation molecule 3; CD229; Ly9
Stability and Storage
Lyophilized protein should be stored at < -20℃, though stable at room temperature for 3 weeks.Reconstituted protein solution can be stored at 4-7℃ for 2-7 days.Aliquots of reconstituted samples are stable at < -20℃ for 3 months
Properties
Human proteins, cDNA and human recombinants are used in human reactive ELISA kits and to produce anti-human mono and polyclonal antibodies. Modern humans (Homo sapiens, primarily ssp. Homo sapiens sapiens). Depending on the epitopes used human ELISA kits can be cross reactive to many other species. Mainly analyzed are human serum, plasma, urine, saliva, human cell culture supernatants and biological samples.
Background
SLAMF3 (CD229) is a type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family. Mature human SLAMF3 consists of a 407 amino acid (aa) extracellular domain (ECD) with two Ig-like V-set and two Ig-like truncated C2-set domains. The ECD of human SLAMF3 shares 57% - 59% aa sequence identity with mouse and rat SLAMF3. Within the first two Ig-like domains that are common to all SLAM proteins, human SLAMF3 shares 24% - 39% aa sequence identity with human 2B4, BLAME, CD2F-10, CD84, CRACC, NTB-A, and SLAM. It is expressed on T and B cells, thymocytes, and more weakly on NK cells. It may participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A. SLAMF3 may be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. It also disable autoantibody responses and inhibit IFN-gamma secretion by CD4+ T-cells and negatively regulate the size of thymic innate CD8+ T-cells and the development of invariant natural killer T (iNKT) cells.